Effects of Gs proteins α subunit T393C genetic polymorphism on carvedlol response in congestive heart failure patients
10.3969/j.issn.1006-5725.2014.21.022
- VernacularTitle:Gs蛋白α亚基T393C多态性对卡维地洛治疗充血性心力衰竭疗效的影响
- Author:
Baoqun LI
;
Haiyan LI
;
Lixian SUN
;
Ruiting WANG
- Publication Type:Journal Article
- Keywords:
Gs proteins α subunit;
Genetic polymorphism;
Carvedlol;
Congestive heart failure
- From:
The Journal of Practical Medicine
2014;(21):3431-3433
- CountryChina
- Language:Chinese
-
Abstract:
Objective To find out the distribution of the subunit of Gs proteins (GNAS1) T393C polymorphism genetic in congestive heart failure patients and to investigate the effects of genetic polymorphisms on the therapeutic efficacy of carvedlol. Methods Genotype of 65 patients with congestive heart failure (heart function was ranked Ⅱ~Ⅳ level by NYHA) underwent PCR-RFLP for GNAS1 polymorphism genetic analysis, and then were treated with carvedlol. The initial dosage of carvedlol was 12.5 mg once daily in patients , and increased by 6.25 mg every 1 ~ 2 weeks for 12 months to a maximum dosage within 50 mg/d. Degree of LVEF changes and heart function improvement was adopted as measuring index , effect of Gs proteins α subunit T393C genetic polymorphism on carvedlol response in congestive heart failure patients was analyzed. Results After carvedlol treatment for 12 months , NYHA class distribution and LVEF in congestive heart failure patients improved significantly (P < 0.05). After carvedlol treatment for 6 months and 12 months mutation symptoms patients′ heart function improved significantly (P < 0.05) and LVEF increased significantly (P < 0.01). Conclusions GNAS1 T393C genetic polymorphism can influence the therapeutic efficacy of carvedlol in chronic congestive heart failure patients. 393 homozygous mutant and mutated symptoms patients′ heart improved more obviously and their LVEF improved more significantly.
